Why ArriVent BioPharma (AVBP) Stock Is Down Today

ArriVent BioPharma (AVBP) is down 52.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp selloff appears tied to ArriVent’s update that its pivotal Phase 3 FURVENT trial for firmonertinib in first-line EGFR exon 20 insertion non-small cell lung cancer did not meet its primary endpoint. For a clinical-stage biotech, a miss in a late-stage study for a lead program can materially reduce expectations for approval, commercialization, and future valuation.

Details:

ArriVent said FURVENT failed to show a statistically meaningful progression-free survival benefit by blinded independent central review versus chemotherapy in the study’s primary analysis.

The company disclosed median progression-free survival of 11.0 months for firmonertinib 240 mg, 8.4 months for 160 mg, and 9.5 months for the control arm, with the 240 mg arm missing significance.

Management noted some favorable secondary measures, including progression-free survival by investigator assessment, objective response data, and an early trend in overall survival, but investors usually focus most heavily on the primary endpoint in pivotal trials.

The setback is especially important because ArriVent had previously highlighted FURVENT as a major late-stage catalyst, even though the company also said it had $373.1 million in cash and investments as of June 30, 2026, which it expected to fund operations into 2028.

Sources:

ArriVent BioPharma, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive AVBP Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$AVBP Hedge Fund Activity

We have seen 98 institutional investors add shares of $AVBP stock to their portfolio, and 45 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VIVO CAPITAL, LLC added 796,181 shares (+89.9%) to their portfolio in Q2 2026, for an estimated $27,659,327
BLACKROCK, INC. added 720,095 shares (+28.5%) to their portfolio in Q2 2026, for an estimated $25,016,100
LOGOS GLOBAL MANAGEMENT LP added 650,000 shares (+185.7%) to their portfolio in Q2 2026, for an estimated $22,581,000
AIHC CAPITAL MANAGEMENT LTD removed 644,788 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,399,935
D. E. SHAW & CO., INC. added 638,687 shares (+273.7%) to their portfolio in Q2 2026, for an estimated $22,187,986
FUND 1 INVESTMENTS, LLC removed 499,990 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $17,369,652
NOVO HOLDINGS A/S removed 442,142 shares (-22.8%) from their portfolio in Q2 2026, for an estimated $15,360,013

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$AVBP Price Targets

Multiple analysts have issued price targets for $AVBP recently. We have seen 2 analysts offer price targets for $AVBP in the last 6 months, with a median target of $44.0.

Here are some recent targets:

Supawat Thongthip from Truist Securities set a target price of $45.0 on 05/29/2026
Yigal Nochomovitz from Citigroup set a target price of $43.0 on 05/13/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.